Lipids and lipid compositions for the delivery of active agents

Patent metadata

Field	Value
Publication number	US-11420933-B2
Application number	US-202017104294-A
Country	US
Kind code	B2
Filing date	Nov 25, 2020
Priority date	Dec 19, 2013
Publication date	Aug 23, 2022
Grant date	Aug 23, 2022

Abstract

This invention provides for a compound of formula (I):or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

First claim

What is claimed is:

1. A method for a treatment of a disease or a condition in a subject in need thereof comprising the step of administering a therapeutically effective amount of a lipid composition comprising
i) a composition of formula (II), or a pharmaceutically acceptable salt thereof,

wherein
R 1 is selected from the group consisting of:

R 2 and R 3 are each, independently, selected from the group consisting of C 7-22 alkyl, C 12-22 alkenyl, C 3-8 cycloalkyl optionally substituted with 1, 2, or 3 C 1-8 alkyl groups,

R 4 is selected from the group consisting of hydrogen, C 1-14 alkyl,

ii) one or more neutral lipids;
iii) one or more helper lipids;
iv) one or more stealth lipids; and
v) a mRNA;
wherein the treatment is ameliorative and/or curative.

2. The method of claim 1 , wherein the compound is selected from the group consisting of:
(9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate;
(9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(dimethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate;
(9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-(((((l-ethylpiperidin-3-yl)methoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate; and
(9Z,9′Z,12Z,12′Z)-2-(((1,3-dimethylpyrrolidine-3-carbonyl)oxy)methyl)propane-1-3-diyl bis(octadeca-9,12-dienoate).

3. The method of claim 1 , wherein the neutral lipids are neutral phospholipids.

4. The method of claim 1 , wherein the neutral lipids are distearoylphosphatidylcholine (DSPC), dioleoyl phosphatidylethanolamine (DOPE), dimyristoyl phosphatidyl ethanolamine (DMPE), or combinations thereof.

5. The method of claim 1 , wherein the helper lipids are steroids, alkyl resorcinols, or combinations thereof.

6. The method of claim 1 , wherein the helper lipid is cholesterol.

7. The method of claim 1 , wherein the stealth lipids are PEG-dimyristylglycerol (PEG-DMG),

or combinations thereof.

8. The method of claim 1 , wherein the lipid composition is in the form of a lipid nanoparticle.

9. The method of claim 1 , wherein the disease or the condition is selected from the group consisting of proliferative disease, inflammatory disease, transplant and/or tissue rejection, autoimmune disease, age-related disease, neurological or neurodegenerative disease, respiratory disease, cardiovascular disease, ocular disease, metabolic disease, dermatological disease, auditory disease, liver disease, and kidney or renal disease.

10. The method of claim 9 , wherein the proliferative disease is cancer.

11. A method for a treatment of cancer in a subject in need thereof comprising the step of administering a therapeutically effective amount of a lipid composition, comprising:
i) a compound, wherein the compound is:

(9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, or a pharmaceutically acceptable salt thereof;
ii) a neutral lipid, wherein the neutral lipid is DSPC;
iii) a helper lipid, wherein the helper lipid is cholesterol;
iv) a stealth lipid, wherein the stealth lipid is S027; and
v) a mRNA;
wherein the treatment is ameliorative and/or curative.

12. The method of claim 11 , wherein the lipid composition comprises
i) about 40 mol % to about 55 mol % (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, or a pharmaceutically acceptable salt thereof;
ii) about 5 mol % to about 15 mol % DSPC;
iii) about 40 mol % to about 55 mol % cholesterol; and
iv) about 1 mol % to about 10 mol % S027.

13. The method of claim 11 , wherein the lipid composition comprises:
i) about 40 mol % to about 50 mol % (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, or a pharmaceutically acceptable salt thereof;
ii) about 5 mol % to about 15 mol % DSPC;
iii) about 40 mol % to about 50 mol % cholesterol; and
iv) about 1 mol % to about 5 mol % S027.

14. The method of claim 11 , wherein the lipid composition comprises:
i) about 43 mol % to about 47 mol % (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, or a pharmaceutically acceptable salt thereof;
ii) about 7 mol % to about 12 mol % DSPC;
iii) about 43 mol % to about 47 mol % cholesterol; and
iv) about 1 mol % to about 4 mol % S027.

15. The method of claim 12 , wherein the lipid composition comprises:
i) about 45 mol % (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, or a pharmaceutically acceptable salt thereof;
ii) about 9 mol % DSPC;
iii) about 44 mol % cholesterol; and
iv) about 2 mol % S027.

16. The method of claim 11 , wherein the lipid composition is in the form of a lipid nanoparticle.

17. The method of claim 11 , wherein the cancer is selected from the group consisting of leukemias, multiple myeloma, AIDS related cancers, breast cancers, bone cancers, brain cancers, cancers of the head and neck, non-Hodgkins lymphomas, adenomas, squamous cell carcinomas, laryngeal carcinomas, gallbladder and bile duct cancers, cancers of the retina, cancers of the esophagus, gastrointestinal cancers, ovarian cancers, uterine cancers, thyroid cancers, testicular cancers, endometrial cancers, melanomas, colorectal cancers, lung cancers, bladder cancers, prostate cancers, pancreatic cancers, sarcomas, Wilms' tumor, cervical cancers, skin cancers, nasopharyngeal carcinomas, liposarcomas, epithelial carcinomas, renal cell carcinomas, gallbladder adeno carcinomas, endometrial sarcomas, and multidrug resistant cancers.

18. The method of claim 11 , wherein the cancer is selected from the group consisting of leukemias, multiple myeloma, breast cancers, brain cancers, ovarian cancers, melanomas, colorectal cancers, lung cancers, prostate cancers, and renal cell carcinomas.

19. The method of claim 11 , wherein the cancer is selected from the group consisting of breast cancers, brain cancers, cancers of the head and neck, melanomas, colorectal cancers, and multidrug resistant cancers.

20. The method of claim 11 , wherein the lipid composition is administered by intratumoral injection.

21. The method of claim 11 , wherein the lipid composition is administered by intramuscular injection.

Assignees

• Novartis Ag

Inventors

• Brito Luis
• Chen Delai
• Gamber Gabriel
• Geall Andrew
• Love Kevin
• Zabawa Thomas
• Zecri Frederic

Classifications

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• C07C271/20

  to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups · CPC title

• C07C219/04

  the carbon skeleton being acyclic and saturated · CPC title

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title